Literature DB >> 18299967

An alternative method for population pharmacokinetic data analysis under noncompliance.

Pankaj Gupta1, Matthew M Hutmacher, Bill Frame, Raymond Miller.   

Abstract

Noncompliance presents a persistent problem while analyzing PK data from outpatient clinical studies. Ignoring dose omission or making uninformed assumptions about patient drug intake history can prove detrimental to the objectives of the analysis (e.g. determining the PK model parameters or identifying covariates) and ultimately compromise the interpretation of the data. In order to overcome this problem, an alternative method of handling noncompliant data is evaluated in this report. The proposed approach is based on the principle of superposition and works by separating the estimation of the elimination rate from the model based steady-state PK concentration. Simulations implementing this method under different scenarios of noncompliance demonstrate that it performs better than the conventional method of analyzing population PK data when compared on the basis of bias and imprecision in parameter estimation and power (and type I error) for covariate detection. Overall, the new method exhibits great potential to address the issue of uncertain/unreliable dosing histories frequently encountered in clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18299967     DOI: 10.1007/s10928-008-9085-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  14 in total

1.  The impact of compliance in pharmacokinetic studies.

Authors:  B Vrijens; E Goetghebeur
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

2.  The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics.

Authors:  W Wang; S P Ouyang
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

3.  Population one-compartment pharmacokinetic analysis with missing dosage data.

Authors:  Dolors Soy; Stuart L Beal; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

4.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

5.  Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.

Authors:  Bernard Vrijens; Eric Tousset; Richard Rode; Richard Bertz; Steve Mayer; John Urquhart
Journal:  J Clin Pharmacol       Date:  2005-04       Impact factor: 3.126

6.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

7.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

8.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

9.  Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine.

Authors:  L L Lim
Journal:  Biometrics       Date:  1992-06       Impact factor: 2.571

10.  Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Authors:  J Lu; J M Gries; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

View more
  11 in total

1.  Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Authors:  Ying Hong; Kenneth G Kowalski; Jenny Zhang; Li Zhu; Mariaarantxa Horga; Richard Bertz; Marc Pfister; Amit Roy
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.

Authors:  Ayyappa Chaturvedula; Michael J Fossler; Craig W Hendrix
Journal:  J Clin Pharmacol       Date:  2013-11-30       Impact factor: 3.126

3.  Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Authors:  Emilie Hénin; Michel Tod; Véronique Trillet-Lenoir; Catherine Rioufol; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.

Authors:  Jonathan Knights; Shashank Rohatagi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-26       Impact factor: 2.745

5.  Methods to detect non-compliance and reduce its impact on population PK parameter estimates.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Valerie Cosson; Nicolas Frey; Franziska Schaedeli Stark
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-21       Impact factor: 2.745

6.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

7.  Methods to account for inaccuracies in the dosing history when performing population pharmacokinetic analysis.

Authors:  Venkata V Pavan Kumar; Stephen B Duffull
Journal:  Pharm Res       Date:  2008-07-08       Impact factor: 4.200

8.  Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.

Authors:  Rebecca N Burns; Craig W Hendrix; Ayyappa Chaturvedula
Journal:  J Clin Pharmacol       Date:  2015-02-04       Impact factor: 3.126

9.  Handling Missing Dosing History in Population Pharmacokinetic Modeling: An Extension to MDM Method.

Authors:  Yuhuan Wang; Xiaoxi Liu
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-01-17

10.  Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.

Authors:  Donald J Irby; Mustafa E Ibrahim; Anees M Dauki; Mohamed A Badawi; Sílvia M Illamola; Mingqing Chen; Yuhuan Wang; Xiaoxi Liu; Mitch A Phelps; Diane R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.